Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors

Virology

Volumn 306, Issue 1, 2003, Pages 147-161

  King, Peter J ^a,c   Lee, Deborah J ^a   Reinke, Ryan A ^a   Victoria, Joseph G ^a   Beale, Keola ^a   Robinson Jr , W Edward ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STEPHEN F AUSTIN STATE UNIVERSITY   (United States)

Author keywords

Acquired immune deficiency syndrome; Biochemistry; Drug resistance; Experimental antiviral agents; HIV replication; Integration; Kinetics; Real Time polymerase chain reaction

Indexed keywords

CICHORIC ACID; INTEGRASE; INTEGRASE INHIBITOR; L 731 988; MUTANT PROTEIN; OXOACID; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CATALYSIS; DNA BINDING; DNA STRAND; ENZYME BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; STEADY STATE; T LYMPHOCYTE; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ACETOACETATES; AMINO ACID SUBSTITUTION; CAFFEIC ACIDS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUCCINATES; VIRUS INTEGRATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0037293099     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(02)00042-9     Document Type: Article

References (65)

1. Andrake M.D., Skalka A.M. Retroviral integrase, putting the pieces together. J. Biol. Chem. 271:1996;19633-19636.
2. Asante-Appiah E., Seeholzer S., Skalka A. Structural determinants of metal-induced conformational changes in HIV-1 integrase. J. Biol. Chem. 273:1998;35078-35087.
3. Asante-Appiah E., Skalka A.M. A metal-induced conformational change and activation of HIV-1 integrase. J. Biol. Chem. 272:1997.
4. Brown P.O. Integration. Coffin J.M., Hughes S.H., Varmus H.E. Retroviruses. 1 ed. 1997;161-203 Cold Spring Harbor Laboratory Press, Plainview, NY.
5. Brown P.O., Bowerman B., Varmus H.E., Bishop J.M. Retroviral integration structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proc. Natl. Acad. Sci. USA. 86:1989;2525-2529.
6. Bujacz G., Alexandratos J., Zhou-Liu Q., Clement-Mella C., Wlodawer A. The catalytic domain of human immunodeficiency virus integrase ordered active site in the F185H mutant. FEBS Letters. 398:1996;175-178.
7. Bujacz G., Jaskolski M., Alexandratos J., Wlodawer A., Merkel G.M., Katz R.A., Skalka A.M. The catalytic domain of avian sarcoma virus integrase conformation of the active-site residues in the presence of cations. Structure. 4:1996;89-96.
8. Bushman F.D., Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci., USA. 88:1991;1339-1343.
9. Butler S.L., Hansen M.S.T., Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nature Med. 7:2001;631-634.
10. Chow S.A. In vitro assays for activities of retroviral integrase. Methods. A Companion to Methods in Enzymology. 12:1997;306-317.
11. Chow S.A., Brown P.O. Juxtaposition of two viral DNA ends in a bimolecular disintegration reaction mediated by multimers of human immunodeficiency virus type 1 or murine leukemia virus integrase. J. Virol. 68:1994;7869-7878.
12. Chow S.A., Brown P.O. Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J. Virol. 68:1994;3896-3907.
13. Chow S.A., Vincent K.A., Ellison V., Brown P.O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science. 255:1992;723-726.
14. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase similarity to other polynucleotidyl transferases. Science. 266:1994;1981-1986.
15. Engelman A., Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 66:1992;6361-6369.
16. Engelman A., Liu Y., Chen H., Farzan M., Dyda F. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J. Virol. 71:1997;3507-3514.
17. Espeseth A.S., Felock P., Wolfe A., Witmer M., Grobler J., Anthony N., Egbertson M., Melamed J.Y., Young S., Hamill T., Cole J.L., Hazuda D.J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA. 97:2000;11244-11249.
18. Farnet C.M., Wang B., Hansen M., Lipford J.R., Zalkow L., Robinson W.E. Jr., Siegel J., Bushman F. Human immunodeficiency virus type 1 cDNA integration new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob. Agents Chemother. 42:1998;2245-2253.
19. Fujiwara T., Mizuuchi K. Retroviral DNA integration structure of an integration intermediate. Cell. 54:1988;497-504.
20. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Tomokazu Y., Fujishita T., Sugimoto H., Endo T., Murai H., Davies D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA. 96:1999;13040-13043.
21. Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R., Davies D.R. Three new structures of the core domain of HIV-1 integrase an active site that binds magnesium. Proc. Natl. Acad. Sci. USA. 95:1998;9150-9154.
22. Greenwald J., Le V., Butler S.L., Bushman F.D., Choe S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry. 38:1999;8892-8898.
23. Hazuda D.J., Pelock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 287:2000;646-650.
24. Heuer T., Brown P. Photo-cross linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry. 37:1998;6667-6678.
25. Jenkins T.M., Esposito D., Engelman A., Craigie R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 16:1997;6849-6859.
26. Johnson M.S., McClure M.A., Feng D.-F., Gray J., Doolittle R.F. Computer analysis of retroviral pol genes assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc. Natl. Acad. Sci.USA. 83:1986;7648-7652.
27. Jones K.S., Coleman J., Merkel G.W., Laue T.M., Skalka A.M. Retroviral integrase functions as a multimer and can turn over catalytically. J. Biol. Chem. 267:1992;16037-16040.
28. Kellogg D.E., Kwok S. Detection of human immunodeficiency virus. Innis M.A., Gelfand D.H., Sninsky J.J., White T.J. PCR Protocols: a guide to methods and applications. 1990;337-347 Academic Press, Inc, San Diego.
29. King P.J., Ma G., Miao W., Jia Q., McDougall B.R., Reinecke M.G., Cornell C., Kuan J., Kim T.R., Robinson W.E. Jr. Structure-activity relationships analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. J. Med. Chem. 42:1999;497-509.
30. King P.J., Robinson W.E. Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 72:1998;8420-8424.
31. Kulkosky J., Jones K.S., Katz R.A., Mack J.P.G., Skalka A.M. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol. Cell. Biol. 12:1992;2331-2338.
32. LaFemina R.L., Schneider C.L., Robbins H.L., Callahan P.L., LeGrow K., Roth E., Schleif W.A., Emini E.A. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 66:1992;7414-7419.
33. Leavitt A.D., Shiue L., Varmus H.E. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J. Biol. Chem. 268:1993;2113-2119.
34. Lubkowski J., Yang F., Alexandratos J., Wlodawer A., Zhao H., Burke T.R. Jr., Neamati N., Pommier Y., Merkel G., Skalka A.M. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. USA. 95:1998;4831-4836.
35. Maignan S., Guilloteau J.-P., Zhou-Liu Q., Clement-Mella C., Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with metal cofactor high level of similarity of the active site with other viral integrases. J. Mol. Biol. 282:1998;359-368.
36. Mazumder A., Engelman A., Craigie R., Fesen M., Pommier Y. Intermolecular disintegration and intramolecular strand transfer activities of wild-type and mutant HIV-1 integrase. Nucleic Acids Res. 22:1994;1037-1043.
37. McDougall B., King P.J., Wu B.W., Hostomsky Z., Reinecke M.G., Robinson W.E. Jr. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob. Agents Chemother. 42:1998;140-146.
38. Miller M.D., Wang B., Bushman F.D. Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate. in vitro. J. Virol. 69:1995;3938-3944.
39. Montefiori D.C., Robinson W.E. Jr., Schuffman S.S., Mitchell W.M. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:1988;231-235.
40. Neamati N., Hong H., Sunder S., Milne G.W., Pommier Y. Potent inhibitors of human immunodeficiency virus type 1 integrase identification of a four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 52:1997;1041-1055.
41. Neamati N., Mazumder A., Sunder S., Owen J.M., Tandon M., Lown J.W., Pommier Y. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase. Mol. Pharmacol. 54:1998;280-290.
42. Pluymers W., Neamati N., Pannecouque C., Fikkert V., Marchand C., Burke T.R. Jr., Pommier Y., Schols D., De Clercq E., Debyser Z., Witvrouw M. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 58:2000;641-648.
43. Poiesz B.J., Ruscetti F.W., Gazder A.F., Bunn B.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA. 77:1980;7415-7419.
44. Pommier Y., Neamati N. Inhibitors of human immunodeficiency virus integrase. Adv. Virus Res. 52:1999;427-458.
45. Reddy M.R.R., Rao M.R., Rhodes D., Hansen M.S.T., Rubins K., Bushman F.D., Venkateswarlu Y., Faulkner D.J. Lamellarin a 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. J. Med. Chem. 42:1999;1901-1907.
46. Reinke R.A., King P.J., Victoria J.G., McDougall B.R., Ma G., Mao Y., Reinecke M.G., Robinson W.E. Jr. Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at non-toxic concentrations. J. Med. Chem. 45:2002;3669-3683.
47. Rice P., Craigie R., Davies D. Retroviral integrases and their cousins. Curr. Opin. Struct. Biol. 6:1996;76-83.
48. Robinson W.E. Jr. HIV integrase the next target. Infect. Med. 15:1998;129-137.
49. Robinson W.E. Jr., Cordeiro M., Abdel-Malek S., Jia Q., Chow S.A., Reinecke M.G., Mitchell W.M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmacol. 50:1996;846-855.
50. Robinson W.E. Jr., Montefiori D.C., Gillespie D.H., Mitchell W.M. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquir. Immune Defic. Syndr. 2:1989;33-42.
51. Robinson W.E. Jr., Reinecke M.G., Abdel-Malek S., Jia Q., Chow S.A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. USA. 93:1996;6326-6331.
52. Roth M., Schwartzberg P., Goff S. Structure of the termini of DNA intermediates in the integration of retroviral DNA dependence on IN function and terminal DNA sequence. Cell. 58:1989;47-54.
53. Sakai H., Kawamura M., Sakuragi J., Sakuragi S., Shibata R., Ishimoto A., Ono N., Ueda S., Adachi A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 67:1993;1169-1174.
54. Sherman P.A., Dickson M.L., Fyfe J.A. Human immunodeficiency virus type 1 integration protein DNA sequence requirements for cleaving and joining reactions. J. Virol. 66:1992;3593-3601.
55. Sherman P.A., Fyfe J.A. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc. Natl. Acad. Sci. USA. 87:1990;5119-5123.
56. Shibagaki Y., Chow S.A. Central core domain of retroviral integrase is responsible for target site selection. J. Biol. Chem. 272:1997;8361-8369.
57. Sotriffer C.A., Ni H., McCammon A. Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. 43:2000;4109-4117.
58. Stevenson M., Haggerty S., Lamonica C.A., Meier C.M., Welch S.K., Wasiak A.J. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J. Virol. 64:1990;2421-2425.
59. Taddeo B., Haseltine W.A., Farnet C.M. Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration. J. Virol. 68:1994;8401-8405.
60. Tramontano E., Colla P., Cheng Y. Biochemical characterization of the HIV-1 integrase 3′-processing activity and its inhibition by phosphorothioate oligonucleotides. Biochemistry. 37:1998;7237-7243.
61. van Gent D.C., Groeneger A.A., Plasterk R.H. Mutational analysis of the integrase protein of human immunodeficiency virus type 2. Proc. Natl. Acad. Sci. USA. 89:1992;9598-9602.
62. Vincent K.A., Ellison V., Chow S.A., Brown P.O. Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations. J. Virol. 67:1993;425-437.
63. Wiskerchen M., Muesing M.A. Human immunodeficiency virus type 1 integrase effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J. Virol. 69:1995;376-386.
64. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., Chen I.S.Y. HIV-1 entry into quiescent primary lymphocytes molecular analysis reveals a labile, latent viral structure. Cell. 61:1990;213-222.
65. Zhu K., Cordeiro M.L., Atienza J., Robinson W.E. Jr., Chow S.A. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J. Virol. 73:1999;3309-3316.